SCHEMBL5695486

SCHEMBL5695486

OC[C@@H]1CN(Cc2ccccc2)CCO1

nearest known ligand 0.71

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 17/20 0.71
DRD2 P14416 4/20 0.65
DRD3 P35462 4/20 0.65
CYP1A2 P05177 1/20 0.63
CYP3A4 P08684 1/20 0.63
CYP2D6 P10635 1/20 0.63
CYP2C9 P11712 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL352001 1.00 DRD4 (0.71) DRD4DRD2DRD3CYP1A2CYP3A4
SCHEMBL1877824 1.00 DRD4 (0.71) DRD4DRD2DRD3CYP1A2CYP3A4
SCHEMBL13229950 0.91 DRD4 (0.59) DRD4DRD2DRD3CYP1A2CYP3A4
SCHEMBL353574 0.89 DRD4 (0.59) DRD4DRD2DRD3CYP1A2CYP3A4
SCHEMBL7371617 0.88 DRD4 (0.76) DRD4DRD2DRD3CYP1A2CYP3A4
SCHEMBL21553759 0.86 DRD4 (0.57) DRD4DRD2DRD3CYP1A2CYP3A4
SCHEMBL17803030 0.86 DRD4 (0.57) DRD4DRD2DRD3CYP1A2CYP3A4
SCHEMBL735729 0.86 DRD4 (0.73) DRD4DRD2DRD3CYP1A2CYP3A4
SCHEMBL2304936 0.86 DRD4 (0.73) DRD4DRD2DRD3CYP1A2CYP3A4
SCHEMBL5748888 0.86 DRD4 (0.73) DRD4DRD2DRD3CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3053923-B1 TRIAZOLOPYRAZINE DERIVATIVES AS TYROSIN KINASE INHIBITORS KOREA RES INST CHEMICAL TECH (KR) 2018-04-11 EP disclosed
EP-3053923-A1 NOVEL TRIAZOLOPYRAZINE DERIVATIVE AND USE THEREOF Korea Research Institute of Chemical Technology (KR) 2016-08-10 EP disclosed
US-9403831-B2 Triazolopyrazine derivative and use thereof KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2016-08-02 US disclosed
US-9403831-B2 Triazolopyrazine derivative and use thereof KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2016-08-02 US disclosed
US-9403831-B2 Triazolopyrazine derivative and use thereof KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2016-08-02 US disclosed
US-20150259350-A1 NOVEL TRIAZOLOPYRAZINE DERIVATIVE AND USE THEREOF HANDOK INC. (KR) 2015-09-17 US disclosed
US-20150259350-A1 NOVEL TRIAZOLOPYRAZINE DERIVATIVE AND USE THEREOF HANDOK INC. (KR) 2015-09-17 US disclosed
US-20150259350-A1 NOVEL TRIAZOLOPYRAZINE DERIVATIVE AND USE THEREOF HANDOK INC. (KR) 2015-09-17 US disclosed
US-9079895-B2 Morpholino compounds, uses and methods UNIVERSITY OF DUNDEE (GB) 2015-07-14 US disclosed
US-9079895-B2 Morpholino compounds, uses and methods UNIVERSITY OF DUNDEE (GB) 2015-07-14 US disclosed
CN-1028527-C Process for preparing coumarin derivatives SANKYO CO (JP) 1995-05-24 CN disclosed
EP-0411912-B1 Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders SANKYO CO (JP) 1995-04-19 EP disclosed
EP-0589484-A1 1,2-Ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same TOYAMA CHEMICAL CO., LTD. (JP) 1994-03-30 EP disclosed
EP-0587194-A1 2-(Heterocycloalkoxy)-1-(subst.-phenyl)-ethanol derivatives as cerebral function improving agents TOYAMA CHEMICAL CO., LTD. (JP) 1994-03-16 EP disclosed
EP-0587193-A1 1,2-Ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same TOYAMA CHEMICAL CO., LTD. (JP) 1994-03-16 EP disclosed
US-5280032-A 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same TOYAMA CHEMICAL CO., LTD. (JP) 1994-01-18 US disclosed
CN-1049662-A Coumarin derivative, preparation thereof and application thereof in treating cerebrovascular disorder SANKYO CO (JP) 1991-03-06 CN disclosed
EP-0411912-A2 Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders Sankyo Company Limited (JP) 1991-02-06 EP disclosed
EP-0383281-A1 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same TOYAMA CHEMICAL CO., LTD. (JP) 1990-08-22 EP disclosed
US-4782054-A ANTIISCHEMIC, ANTIHYPOXIC, STIMULANTS ADIR ET COMPAGNIE (FR) 1988-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150259350-A1 NOVEL TRIAZOLOPYRAZINE DERIVATIVE AND USE THEREOF MET, RET, BRAF DRD4 624/4885DRD2 873/4885DRD3 1164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.